If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Emcure has launched an awareness campaign to help spread the word about male anemia
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
The company uses iPS cells to develop treatments for diseases relating to the kidney
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Subscribe To Our Newsletter & Stay Updated
